Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Open-label, Multicentre, Single Arm Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Chinese Paediatric Participants With Central Precocious Puberty.

NCT05029622 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT05029622
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05029622 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Open-label, Multicentre, Single Arm Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Chinese Paediatric Participants With Central Precocious Puberty.
Lead sponsor
Ipsen
Phase
Phase 3
Overall status
Completed
Start date
August 10, 2021
Completion date
February 13, 2023
Enrollment
66 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

central precocious puberty